Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Prostate Drugs Market Share

Wednesday, January 11, 2017 4:23
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Zytiga has highest market share in Prostate Cancer Market share globally. Zytiga is facing hard fight from Xtandi drugs which is anticipated to substitute Zytiga as the primary prostate cancer drugs in 2015. Zytiga was one of a small number of treatment choices for patients suffering from prostate cancer. This shows that most doctors prefer to treat patients with Zytiga drug despite its side effects. Before September 10, 2014 Xtandi, was given to only those patients who have previously received chemotherapy. But after September 10, 2014, Xtandi was permitted to be used as treatment choice for pre–chemotherapy prostate cancer patients.

Out of 15 Prostate Drugs Market share only 4 drugs (Zytiga, Zoladex, Leuplin & Xtandi or MDV3100) have double digit market share in prostate cancer drugs market. All these four drugs together account for more than 60 percent market share. Zytiga market share is more than double from its nearest competitor Leuplin. 

Prostate Drugs Market Share

 

Contact Us

Renub Research 
USA: +1-678-302-0700
India: +91-120-421-9822
Email: info@renub.com 
Website: www.renub.com 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.